

# Matthew Siegel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12048063/publications.pdf>

Version: 2024-02-01

17  
papers

1,674  
citations

567281

15  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1602  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Patients With Celiac Sprue. <i>Gastroenterology</i> , 2007, 133, 472-480.	1.3	205
2	Extracellular Transglutaminase 2 Is Catalytically Inactive, but Is Transiently Activated upon Tissue Injury. <i>PLoS ONE</i> , 2008, 3, e1861.	2.5	174
3	Transglutaminase 2 inhibitors and their therapeutic role in disease states. , 2007, 115, 232-245.		170
4	Chemistry and Biology of Dihydroisoxazole Derivatives: Selective Inhibitors of Human Transglutaminase 2. <i>Chemistry and Biology</i> , 2005, 12, 469-475.	6.0	154
5	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. <i>Clinical Immunology</i> , 2010, 134, 289-295.	3.2	125
6	Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform. <i>Stem Cell Reports</i> , 2017, 9, 1976-1990.	4.8	122
7	Rational Design of Combination Enzyme Therapy for Celiac Sprue. <i>Chemistry and Biology</i> , 2006, 13, 649-658.	6.0	117
8	Effect of Pretreatment of Food Gluten With Prolyl Endopeptidase on Gluten-Induced Malabsorption in Celiac Sprue. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 687-694.	4.4	93
9	Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	91
10	Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2012, 57, 440-450.	2.3	88
11	Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6565-6573.	3.0	85
12	Inhibition of HLA-DQ2-Mediated Antigen Presentation by Analogues of a High Affinity 33-Residue Peptide from $\hat{\iota}$ 2-Gliadin. <i>Journal of the American Chemical Society</i> , 2006, 128, 1859-1867.	13.7	73
13	Transglutaminase 2 Regulates Mallory Body Inclusion Formation and Injury-Associated Liver Enlargement. <i>Gastroenterology</i> , 2007, 132, 1515-1526.	1.3	66
14	Structure-based design of $\hat{\iota}$ -amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6253-6261.	3.0	41
15	Interferon- $\hat{\iota}$ 3 Released by Gluten-Stimulated Celiac Disease-Specific Intestinal T Cells Enhances the Transepithelial Flux of Gluten Peptides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 657-668.	2.5	37
16	Tissue transgluaminase 2 expression in meningiomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 125-132.	2.9	19
17	Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation. <i>FEBS Letters</i> , 2006, 580, 2351-2357.	2.8	14